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Attenuated Vibrio cholerae oral vaccineCVD 103-HgR waswelltolerated by 324 Thai soldiers
and civilians. Most receiveda single 5 X 108 cfu dose, while 40 each receivedone or two 5 X 109
cfu doses. Vibriocidal antibody (the best correlate of immunity) seroconversion was lower in
soldiers than civilians (P < .001). Increasing the vaccinedose to 5 X 109 cfu raised the geometric
mean titer (P < .001). A second 5 X 109 cfu dose one weeklater did not notably increase serocon-
versions. Likelihood of seroconversionwas inverselycorrelated with baseline vibriocidal titer (P
< .001). CVD 103-HgR caused seroconversion in most subjects with baseline titers .;;1:40, in-
cluding 100% of civiliansafter one 5 X 108 cfu dose, 79% of soldiers after one 5 X 109 cfu dose,
and 45% of soldiers after one 5 X 108 cfudose. In persons with elevatedbaselinetiters, vibriocidal
antibody seroconversion is not a sensitive measure of whether vaccine has boosted intestinal
immunity; for such subjects,other measurements must be used. Study regimens in endemic areas
should use a single 5 X 109 cfu dose.
Cholera remains an important public health problem in
less-developed countries, spreading readily where sanitation
is compromised and often appearing in explosive epidemics.
The World Health Organization has targeted the develop-
ment of an improved cholera vaccine as a priority [I, 2] be-
cause the parenteral inactivated whole cell vaccine, which
provides only limited, short-lived protection, can play no
practical role in cholera control [3]. An ideal new cholera
vaccine would be well tolerated and rapidly stimulate a high
level of long-term protection among all age groups after ad-
ministration ofjust one oral dose. Such a vaccine would con-
stitute a welcome addition to the public health intervention
measures available to control epidemic and endemic cholera.
An important advance in immunization against cholera
was documented several years ago in a field trial in Bangla-
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desh when two related inactivated oral cholera vaccines (one
consisting of inactivated Vibrio cholerae 0 I organisms and
the other of inactivated organisms plus the B subunit ofchol-
era toxin) were each shown to confer 50% protection for 3
years [4]. That experience illustrates that oral vaccines can
elicit relatively long-lived protection against cholera. How-
ever, the field trial in Bangladesh also exposed notable defi-
ciencies of those oral inactivated vaccines: Multiple, spaced
doses were required to elicit protection, young children (the
population with the highest incidence ofcholera in that area)
were least protected, and despite administration of three
spaced doses, the level of efficacy was only 50%-52% [4].
With attenuated strains of V. cholerae 0 I as live oral vac-
cines, it may be possible to overcome the drawbacks of the
oral inactivated vaccine and to protect satisfactorily after just
one dose ofvaccine. CVD I03-HgR is an attenuated strain of
V. cholerae 0 I derived from wild-type classical lnaba strain
569B by deleting the genes that encode the A subunit of
cholera toxin [5] and by inserting a gene encoding resistance
to Hg2+ into the hlyA locus of the chromosome [6, 7]. CVD
103-HgR has been given to ~ 1500 adults and children in
phase I and 2 clinical studies in industrialized and in less-de-
veloped countries; the vaccine was well tolerated with no
adverse reactions attributable to the vaccine over the back-
ground frequency of reaction among placebo recipients.
Since vibriocidal antibody is currently recognized as the
best correlate of protection and of the successful stimulation
of antibacterial immunity (whether infection- or vaccine-
derived) [8-11], measurement of the serum vibriocidal
antibody response has been used as the main gauge of the
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immunogenicityofCVD 103-HgR[6, 12, 13]. Theimmuno-
genicity of this vaccine has been consistently impressive in
adults in industrialized countries [6, 7, 12]. For example,
92% of US adults who ingested a single oral dose containing
5 X 108 cfu of CVD 103-HgR showed fourfold or greater
rises in serum vibriocidal antibody, 49% reached titers
;;;.1 :2560, and the geometric mean titer (GMT) was 1596
(unpublished data). Similar results were observed in Swiss
adults who received a single 5 X 108 cfu oral dose of CVD
103-HgR [8]. Titers of;;;. I :2560 arbitrarily have been consid-
ered high and previously have been used as a useful parame-
ter in evaluations of oral cholera vaccines [6, 8, 12-15].
On the basis of encouraging results obtained in adults in
industrialized countries, a preliminary study ofthe safety and
immunogenicity ofCVD I03-HgR was done in young adults
under containment in the Research Ward ofMahidol Univer-
sity's Vaccine Trial Centre [13]; 24 subjects were random-
ized to receive a single 5 X 108 cfu oral dose of CVD 103-
HgR or placebo. In this study the vibriocidal antibody
responses surpassed those recorded for North Americans.
Following that initial inpatient volunteer study in Thailand,
we carried out a series of additional phase 2 field studies in
Thailand to assess the safety and immunogenicity of CVD
103-HgR. Here we report results ofa series ofstudies in Thai
soldiers and civilians that compares different dosages, immu-
nization schedules, and lots of this oral vaccine.
Materials and Methods
Vaccine and Placebo Preparations
The vaccine formulation consisted of two packets: One con-
tained lyophilized vaccine (5 X 108 or 109 cfu) with aspartame,
while the other contained buffer (2.5 g ofNaHC03 and 1.65 g of
ascorbic acid). A packet of vaccine and a packet of buffer were
mixed in a cup containing 100 ml of water and the suspension
was given orally to healthy subjects. In some studies controls
received a placebo preparation consisting ofa packet containing
5 X 108 inactivated, lyophilized Escherichia coli K12. The pla-
cebo powder appeared identical to the vaccine before and after
mixing with buffer.
Subjects
Volunteers were soldiers in the Royal Thai Army or civilians
18-26 years of age. None of the Royal Thai Army soldiers had
received parenteral inactivated whole cell cholera vaccine previ-
ously.
Study Design
Four studies were done during February 1988-June 1991 in
Thai soldiers or civilians.
Study I, February /988. A total of 206 Thai soldiers were
randomly allocated to receive one 5 X 108 cfu dose of CVD
Table 1. Design of study 4 to evaluate tolerance and immunoge-
nicity of different immunization regimens oflive oral cholera vac-
cine CVD 103-HgR in Thai soldiers.
Preparation* given on day
Group 0 7
A 5 X 109 5 X 109
B Placebo 5 X 109
C 5 X 109 Placebo
D 5 X 108 Placebo
E Placebo 5 X 108
F 5 X 109 5 X 109
*Colony-forming units ofattenuated vaccine strain CVD 103-HgR.
I03-HgR oral vaccine or placebo and were examined daily for 7
days for adverse reactions. Serum for antibody measurement
was collected before and 9, 21, and 28 days after vaccination.
Study 2, November /988. Forty Thai soldiers were vacci-
nated orally with one 5 X 108 cfu dose of vaccine. They were
randomized to receive doses from either the identical lot ofvac-
cine that was used in study I or another lot. Subjects were moni-
tored for 7 days for adverse reactions, and sera were collected
before and 9 and 28 days after vaccination for antibody measure-
ment.
Study 3, March /989. A group of 33 soldiers and a group of
30 civilians each received a single 5 X 108 cfu oral dose from the
identical lot of vaccine given identically under supervision of
the same clinical investigator. Subjects were followed for 7 days
for adverse reactions, and sera were obtained before and 9 and
28 days after vaccination.
Study 4, June /99/. The unexpectedly low overall rates of
vibriocidal antibody seroconversion of soldiers given a single 5
X 108 cfu dose of CVD 103-HgR led us to design a study to
answer several practical questions: Whether a single 5 X 109 cfu
dose would be significantly more immunogenic than a 5 X 108
cfu dose; whether a second 5 X 109 cfu dose of vaccine I week
after the first dose would enhance immunogenicity; and whether
the same regimen of vaccine given to several different groups of
subjects would result in immune responses that were consistent.
We attempted to answer these questions in a randomized, multi-
group (20 subjects/group), double-blind, crossover study (ta-
ble 1).
The 120 orally vaccinated subjects were followed for 14 con-
secutive days to detect adverse reactions. Sera were collected
before and 7, 14, 21, and 28 days after the first dose of vaccine
or placebo.
Definitions of Adverse Reactions
Diarrhea was defined as the passage of at least four loose
stools within a 24-h period. One or more episodes of emesis was
considered vomiting.
Serologic Methods
Inaba vibriocidal antibody was measured by the microtiter
method [16]; fourfold or greater rises in titer were considered
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significant (seroconversion). IgG cholera antitoxin was mea-
sured by ELISA in serum specimens diluted 1:50 as previously
described [17]; when the net optical density (aD) of the prevac-
cination specimenwas ;;--1.00, serum specimenswere retested at
a dilution of I:400. A ;;--0.15 rise in net Ol) of the postvaccina-
tion specimenover that of the prevaccination specimenwascon-
sidered significant [17] (seroconversion).
Statistical Methods
Proportions were compared by x2 or Fisher's exact test.
GMTs were compared by t tests using log-transformeddata.
Results
Safety
CVD I03-HgR live oral cholera vaccine was well tolerated
by the Thai adults. No diarrheal illness was observed in the
open studies (studies 2 and 3), either in soldiers or in civi-
lians. In the two placebo-controlled studies (studies I and 4),
no increased rate of diarrheal episodes or other gastrointesti-
nal adverse reactions was observed among vaccine than
among placebo recipients. Diarrhea was recorded in II %of
102 vaccinees compared with 12.5%of 104 controls in study
I; in study 4 diarrhea was observed in 2.5%of 119 vaccinees
compared with 2.5% of 79 controls. One subject in the vac-
cine group in study 4 passed eight loose stools and sought
health care. This event occurred 3 days after the subject had
received his second 5 X 109 cfu dose of vaccine. A coprocul-
ture was not obtained during the diarrheal episode. Notably,
this subject did not develop a rise in vibriocidal antibody or
in antitoxin levels, suggesting that the diarrheal episode was
due to another cause.
Immunogenicity
Vibriocidal antibody response. In study I, only 20%ofthe
95 soldiers tested who received a single 5 X 108 cfu dose of
CVD 103-HgR oral vaccine developed significant rises in
vibriocidal antibody and only 2% reached titers » l :2560 (ta-
ble 2). This serologic response was markedly inferior to that
of adults in industrialized countries given this dose of vac-
cine and to that of the first 12 young Thai adults at Mahidol
University who participated in the preliminary study ofCVD
103-HgR (92% of whom had seroconversions in Inaba vi-
briocidal antibody with a peak GMT of 3417) [13]. Because
of this unexpectedly poor serologic response, a second study
was done in which 40 Thai soldiers were randomly allocated
to receive a single 5 X 108 cfu dose ofCVD 103-HgR, either
from the same lot of vaccine that was used in study I or from
another lot. Vibriocidal seroconversion was 25% in each
group (table 2). In one of these groups, five subjects had
vibriocidal titers ;;-- I :2560. Study 2 showed that the poor sero-
logic response of Thai soldiers to a single 5 X 108 cfu dose of
CVD 103-HgR was apparently a consistent finding and not
due to one particular lot of vaccine. Moreover, the presence
of moderate (and occasionally high) baseline titers of vibrio-
cidal antibody in some soldiers suggested that within this
population there exist individuals who are already immune
to cholera, presumably by having had inapparent or clini-
cally mild cholera previously. These observations also sug-
gested that Thai soldiers might represent an inherently dif-
ferent host than Thai civilians, despite the fact that the
baseline vibriocidal GMT of the latter also suggested some
prior exposure to cholera in this endemic area.
To investigate these possibilities, study 3 was done in May
1989, when one lot ofCVD 103-HgR was used to vaccinate
Thai soldiers or civilians with a single 5 X 108 cfu dose. As
summarized in table 2, the identical lot ofvaccine was signifi-
cantly less immunogenic in soldiers than in civilians.
The observations made in study 3 led us to explore practi-
cal ways to enhance the serologic response ofThai soldiers to
CVD 103-HgR. The design of study 4 permitted us to pursue
several objectives. The firstwas a comparison ofthe immuno-
genicity of a single dose of CVD 103-HgR containing 5 X
109 cfu rather than 5 X 108 cfu. The second objective was to
assess the variability of the serologic response of several dif-
ferent groups of Thai soldiers to a single 5 X 109 cfu dose of
CVD 103-HgR. The last objective was to measure the rela-
tive immunogenicity of two 5 X 109 cfu doses of CVD 103-
HgR given I week apart.
Table 3 summarizes the vibriocidal response in subjects in
study 4 who received two 5 X 109 cfu doses, one 5 X 109 cfu
dose, or one 5 X 108 cfu dose ofCVD 103-HgR vaccine. In
this summary analysis that combines data from several differ-
ent groups who received the same regimen, there appears to
be a modest gradient ofserologic response, with the two-dose
5 X 109 cfu regimen stimulating the best response and the
single 5 X 108 cfu dose regimen eliciting the weakest re-
sponse. The effect ofgiving a second dose of vaccine I week
after the first 5 X 109 cfu dose is also shown in table 3. While
20 of 40 subjects seroconverted after one dose, the second
dose led to only three additional seroconversions, raising the
total number of seroconvertors to 23 of 40.
Upon further analysis, the difference in GMT between the
subjects who received two 5 X 109 cfu doses of vaccine and
those who received one 5 X 109 cfu dose (table 3) is seen
largely to be an artifact unrelated to the number of doses;
that is, the marked difference in vibriocidal response among
the various groups was already evident after just a single dose
oforal vaccine. This is illustrated in table 4, where the vibrio-
cidal response of groups who received a single dose of 5 X
109 cfu (B and C) can be compared with the vibriocidal re-
sponse after the first 5 X 109 cfu dose ofvaccine of groups (A
and F) who eventually received a second dose. For this rea-
son, only baseline and 7-day postvaccination titers are com-
pared. In this analysis the high GMT ofgroup F has already
occurred after just one oral dose of vaccine. Indeed, the
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Table 2. Serum vibriocidal and antitoxin responses ofThai soldiers and civilians after a single dose
of 5 X 108 cfu of CVD 103-HgR live oral cholera vaccine in field studies during 1988 and 1989.
Geometric
mean titer No. (%)with
Study, %with titers serum antitoxin
group (n) %seroconverting ;;'1:2560 Day 0 Peak seroconversion
Soldiers (95)* 20 2 81 149 22* (22)
2
Soldiers" (20) 25 25 219 557 5 (25)
Soldiers; (20) 25 0 104 260 5 (25)
3
Soldiers (33) 391 01 80 238 3 (27)'
Civilians (30) 631 401 142 1470 16 (53)'
* Of 102 subjects vaccinated, paired sera were obtained from 95.
t Same vaccine lot as used in study I.
; Different lot from that used in study I.
I P = .079, Ip < .001. two-tailed Fisher's exact test;'p = .064, x 2 test with Yates's correction.
GMT ofgroup F on day 7 (597) after just one dose ofvaccine
is already significantly higher than that ofgroup A (269), the
group with the lowest GMT of the four groups. Comparing
GMTs ofall groups on day 7 (table 4) shows that a single 5 X
109 cfu dose of CVD 103-HgR always resulted in a higher
GMT than did a single 5 X 108 cfu dose oforal vaccine. The
GMT (368) on day 7 after vaccination of the 80 subjects who
had one 5 X 109 cfu dose of oral vaccine (includes the re-
sponse after the first dose of the 40 vaccinees who went on to
receive a second dose on day 7) was significantly higher than
that ( 191) of the 39 subjects who received a single 5 X 108
cfu dose of vaccine (P = .016).
The kinetics of the vibriocidal antibody responses mea-
sured on days 0, 7, and 21 in the various groups of soldiers
who received the different immunization regimens is shown
in figure I.
The high baseline vibriocidal titers recorded in many of
the Thai soldiers suggested that previous antigenic experi-
ence with V. cholerae 0 I rendered them already immune. In
such subjects the lack of rise in serum vibriocidal antibodies
might not adequately reflect the immunologic status of these
individuals. To investigate this hypothesis, we analyzed the
baseline vibriocidal antibody titers of seroconvertors and
nonseroconvertors to determine if those of the latter were
higher, thereby providing serologic evidence of prior anti-
genic contact with cholera vibrios. Among soldiers who re-
ceived the 5 X 109 cfu dose of vaccine, the baseline GMT of
the 40 nonseroconvertors (132) was significantly higher than
that of the seroconvertors (45, P < .00 I). This inverse rela-
tionship also held true for the soldiers who received the 5 X
108 cfu dose of vaccine. Among the 207 soldiers who re-
ceived this dose, the prevaccination vibriocidal GMT of the
144 nonseroconvertors (112) was significantly higher than
the baseline GMT of the 63 soldiers who seroconverted (61,
P < .001). Seroconversion in relation to specific prevaccina-
tion Inaba vibriocidal titers is shown in table 5 for soldiers
given either dose of vaccine. It is clear that the higher the
baseline titer, the lower the percentage of seroconversion.
Among the 30 civilians who received a single 5 X 108 cfu
dose ofvaccine, the baseline Inaba vibriocidal antibody level
Table 3. Serum vibriocidal antibody response of groups of volunteers after ingesting live oral
cholera vaccine CVD 103-HgR (study 4, June 1991).
Geometric mean titer on
day
%with postvaccine
Vaccine regimen (n) %seroconverting titers ;;.1:2560 0 7 21
5 X 109 *,2 doses" (40) 58 23 67 401 320
5 X 109• 1 dose (40) 43 20 100 337 220
5 X 108 *, I dose (39) 33 21 81 191 175
Placebo, I dose (39) 2 0 87 101
* Colony-forming units in one dose of vaccine.
t Doses given 7 days apart.
; Seroconversion after one dose was 20 (50%) of 40; 13% reached titers ;;'1:2560.
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Table 4. Serum vibriocidal antibody response in groups ofvolunteers 7 days after ingesting a single
dose of live oral cholera vaccine CVD 103-HgR.
%(CI) with Geometric mean titer (CI) on day
vibriocidal No. with
Group (n). regimen seroconversion titers > I:2560 0 7
A (20)
5 X 109 50 (27-73) 4 51 (31-85) 269 (154-469)
B (20)
5 X 109 40 (23-64) 2 121 (63-235) 279 (165-470)
C (20)
5 X 109 45 (23-65) 6 83 (46-148) 408 (162-1029)
F (20)
5 X 109 50 (27-73) 5 89(47-167) 597 (327-1092)
0(19)
5 X 108 26 (9-51) 3 77 (52-115) 185 (103-332)
E (20)
5 X 108 40 (19-64) 2 86 (53-139) 197 (111-351)
All recipients (80)
5 X 109 48 15 82 368*
All recipients (39)
5 X 108 33 5 81 191*
NOTE. All groups received one dose at the number of colony-forming units indicated. CI, 95% confidence
interval.
*P=.016.
among the II nonseroconvertors (GMT = 265) was signifi-
cantly higher than that of the 19 seroconvertors (GMT =
100;P = .02, t test). The percentage of seroconversion in the
civilians also diminished with increasing baseline titer (table
5). However, among the civilians given a single dose of 5 X
108 cfu, significantly higher percentages of seroconversion
were observed among those who had baseline titers of'< I:40;
6 (100%) of 6 seroconverted. In contrast, of the 64 soldiers
with baseline titers « I:40 who received a single 5 X 108 cfu
dose oforal vaccine, only 45%seroconverted (P = .025). The
percentage of seroconversion in soldiers with low (,,;; I:40)
baseline titers was significantly higher when they were given
a log-higher dose of vaccine (79% vs. 45%, P = .006).
Antitoxin Response
The percentages ofIgG antitoxin seroconversion detected
in serum generally paralleled the patterns ofvibriocidal sero-
conversion in the four studies. Data from studies 1-3 are
summarized in table 2. In study 4, significant rises in serum
IgG antitoxin occurred in 58% of the 40 soldiers who re-
ceived two 5 X 109 cfu doses, 43%ofthe 40 who got one 5 X
109 cfu dose, and 41%of the 39 soldiers who got a single 5 X
108 cfu dose of vaccine.
Discussion
The critical role played by antibacterial, rather than anti-
toxic, immunity in long-term protection against cholera is
becoming increasingly recognized [4, 14, 15, 18]. Hereto-
fore, evaluations of the immunogenicity ofCVD I03-HgR in
various populations have used serum vibriocidal antibody
response as the measure of antibacterial immunity and as a
correlate of elicited protection [6, 12, 13]. In populations
from industrialized countries, representing individuals who
lack background immunity to V. cholerae 0 I, this measure-
ment of serum antibody has been remarkably useful for de-
termining vaccine "take."
While a single 5 X 108 cfu dose of CVD 103-HgR has
consistently elicited 80%-95% vibriocidal seroconversion in
persons from industrialized countries, it has been equally
consistent in eliciting only 20%-50%seroconversion in Thai
soldiers. The series of studies in Thailand provides several
insights into the reasons for this. One observation is that the
vibriocidal response of soldiers to a 5 X 108 cfu dose ofCVD
103-HgR is significantly less than that of civilians of similar
age, demonstrating host differences (table 2). Civilians were
more often urban and from middle socioeconomic back-
ground, while the soldiers were more commonly of rural and
lower socioeconomic background.
We hypothesize that at least two factors playa role in the
lower serum vibriocidal antibody seroconversion in soldiers:
Preexisting background immunity against V. cholerae 0 I and
levels of microflora in the proximal small intestine. Back-
ground immunity in some soldiers would limit intestinal co-
lonization of the vaccine strain in these individuals. While
live oral cholera vaccine would likely boost mucosal immu-
nity in the intestine, such local boosting might not be re-
flected by a rise in serum vibriocidal antibodies. Indeed,
three observations strongly support this contention.
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9/16 (56)
3/13 (23)
17/35(49)
17/51 (33)
II/51 (22)
3/26(12)
3/10 (30)
0/5(0)
29/64 (45)
34/143 (24)
Soldiers
8/8 (100)
8/11 (73)
6/9(67)
8/21 (38)
6/17 (35)
3/9(33)
0/2(0)
0/1 (0)
22/28 (79)
17/50 (34)
Civilians
5 X 108
3/3(100)
2/2 (100)
1/1 (100)
3/3(100)
3/9(33)
4/7(57)
3/4(75)
0/1 (0)
6/6*t (100)
13/24 (54)
NOTE. Data are given asno. ofvaccinees with fourfold orgreater rises/
no. vaccinated (%).cfu, colony-forming units.
* 6/6vs. 29/64, P = .025; t 22/28 vs. 29/64. P = .006; two-tailed Fisher's
exact test.
Group, cfu
1:10
1:20
1:40
1:80
1:160
1:320
1:640
;;>1:1280
~1:40
>1:40
Titer
Table 5. Preimmunization Inaba vibriocidal antibody titers and
numbers of Thai civilians and soldiers whoseroconverted after in-
gesting a single dose of CVD-103Hg-R live oral cholera vaccine.
successful stimulation of antibacterial immunity in individ-
uals who lack previous antigenic stimulation by V. cholerae
01 (such as subjects in industrialized countries), it is not a
sensitive measure for determining whether successful boost-
ing has occurred in antigenically primed individuals (such as
adults in areas endemic for cholera). Future immunogenicity
studies will need to take this into account and may have to
include measurements offecal or jejunal secretory IgA anti-
bodies and gut-derived trafficking IgA antibody-secreting
cells (detected in peripheral blood) to ascertain whether in-
testinal mucosal immunity has been successfully boosted in
vaccinees with antecedent immunity.
Another factor affecting the take after administration of
live oral bacterial vaccines may be differences in intestinal
microflora. Adults and children living under low socioeco-
nomic conditions in less-developed countries are known to
have increased levels ofanerobic and coliform microflora in
their proximal small intestine compared with persons from
industrialized countries [21-23j. These elevated levels of
proximal intestinal microflora are associated with morpho-
logic changes that include flattening of the villi [24, 25j.
These microflora may serve as a barrier to successful vaccine
take by CVD 103-HgR, which must compete with existing
microflora to colonize and elicit immune responses. Some of
the Thai civilians also had elevated baseline vibriocidal titers
and, as expected, showed less seroconversion (table 5). How-
ever, civilians with low baseline titers had significantly
higher percentages of seroconversion than did soldiers with
the same baseline titers. This result would suggest that in the
soldiers other factors, in addition to baseline titer, were opera-
tive in diminishing the vaccine take. We hypothesize that the
2821
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First, some soldiers do have quite elevated vibriocidal
titers at baseline. A vibriocidal antibody titer of I: 1280 has
been cited as suggestive of recent cholera infection [l0j. A
total of9 (2.4%)of the 368 soldiers who participated in these
studies whose sera were tested (284 vaccinees and 84 con-
trois) had titers ~ I: 1280 before vaccination despite the lack
of previous cholera vaccination. Second, seroconversion
after CVD 103-HgR vaccination was found to be strongly
inversely related to the baseline vibriocidal antibody titer.
Nonseroconvertors had a significantly higher baseline GMT
than did seroconvertors, and the higher the baseline titer, the
lower the percentage of seroconversion (table 5). The final
evidence comes from groups of North American volunteers
who developed experimental cholera while serving as con-
trols in vaccine efficacy studies and who were then rechal-
lenged with pathogenic V. cholerae 0 I 2 months to 3 years
later [10, 18-20]. These volunteers showed prominent rises
in titer of serum vibriocidal antibody after their initial clini-
cal cholera infection, which fell over 1-12 months to a level
that was nevertheless above baseline [IOJ. While these volun-
teers were solidly protected against cholera upon rechallenge
with an 1090 ofwild-type vibrios [10, 18-20j, they either did
not show rises in serum vibriocidal antibody upon rechal-
lenge or showed only modest rises [10, 20j.
The above observations demonstrate that while serum vi-
briocidal antibody is an excellent means to document the
DAYSAFTERSTARTOFSTUDY
Figure 1. Kinetics of serum vibriocidal antibody response in
crossover study of live oral cholera vaccine strain CVD 103-HgR
(study 4). Volunteers received either placebo (killed Escherichia
coli K12) or vaccine on day 0 or 7. Groups A and F received 5 X
109 cfuof vaccine on both days. Groups Band E received placebo
on day 0 and 5 X 109 cfu and 5 X 108 cfu, respectively, on day 7
(arrows). GroupsC and D received 5 X 109 and 5 X 108, respec-
tively, on day0, and both received placebo on day 7.
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combination of elevated baseline titers and increased levels
of microflora in the proximal small intestine (if present) in
the soldiers might work in tandem to effectively diminish the
dose of CVD 103-HgR organisms that reach the intestinal
immune system.
On the basis of the above observations, we asked whether
simply increasing the dose of CVD 103-HgR to 5 X 109 cfu
could adequately enhance immunogenicity. In the fourth of
our studies of Thai adults reported here, a single dose of
CVD 103-HgR containing 5 X 109 cfu elicited higher GMTs
than did a single dose containing 5 X 108 cfu. More dramatic
supportive data come from studies in Indonesian children
5-9 years old, in whom a single 5 X 108 cfu dose of CVD
103-HgR stimulated seroconversion in only 16%, while a sin-
gle 5 X 109 cfu dose of the same lot of vaccine elicited sero-
conversion in 79%(unpublished data).
This series ofstudies emphasizes the complexity ofthe oral
route of immunization, the importance of obtaining data
from several immunogenicity studies before drawing conclu-
sions, and the need to develop simple, practical ways ofmea-
suring boosting of the intestinal immune system in individ-
uals with background immunity. In these various studies of
immunogenicity we measure serologic responses as a proxy
for the elicitation of protective immunity. Ultimately, direct
evidence ofprotection in these populations must be garnered
from carefully designed and conducted field trials of efficacy
under natural conditions of challenge. The results of such
studies will put the serologic responses in proper perspective.
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